loading page

Monomorphic Post-Transplant Lymphoproliferative Disorder in Pediatric Solid Organ Transplant Recipients: Treatment Approach Across Canada
  • +3
  • Catherine Mark,
  • Gina Martin,
  • Bjorn Baadjes,
  • Ashley V. Geerlinks,
  • Angela Punnett,
  • Lucie Lafay-Cousin
Catherine Mark
The Hospital for Sick Children

Corresponding Author:[email protected]

Author Profile
Gina Martin
Saskatoon City Hospital Foundation
Author Profile
Bjorn Baadjes
BC Children's Hospital
Author Profile
Ashley V. Geerlinks
London Health Sciences Centre Children's Hospital
Author Profile
Angela Punnett
The Hospital for Sick Children
Author Profile
Lucie Lafay-Cousin
Alberta Children's Hospital
Author Profile


There are no standardized pediatric treatment protocols for monomorphic post-transplant lymphoproliferative disorder (PTLD). We reviewed data from Canadian pediatric centers to determine patient characteristics, treatment approaches and outcomes. There were 55 eligible children diagnosed with monomorphic PTLD between January 2001-December 2021. Forty-nine (89%) underwent reduction of immunosuppression. The majority, 44 (80%), received rituximab, 40/44 (91%) with concurrent chemotherapy. A total of 46 (84%) children received chemotherapy: LMB-96 (48%) and low-dose cyclophosphamide with prednisone (30%) being the favored regimens. Projected 3-year event-free survival and overall survival was 62% and 77%, respectively. Approach to monomorphic PTLD treatment was relatively consistent across Canada.